Bernd Eisele
Chief Executive Officer at Vakzine Projekt Management GmbH
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stefan Kaufmann | M | 76 |
Vakzine Projekt Management GmbH
 Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Peter Buckel | M | 79 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Leander Grode | M | 54 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Peter Lange | M | 80 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Rolf Guenter Werner | M | - |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Michael Manns | M | 73 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Michael Bröker | M | - |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Inge Jacobi | F | 61 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | 21 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Albrecht Laeufer | M | - |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | 5 years |
| Valentin Chapero Rueda | M | 68 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Henning Weigt | M | 50 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Ernst-Günter Afting | M | 80 |
Behringwerke AG
 Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | 5 years |
| Michael Odenwald | M | 66 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Hans Moebius | M | 68 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Michael Christian Knorz | M | 65 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Angelica Kohlmann | M | 64 |
Behringwerke AG
Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | 2 years |
| Setsuko Hashimoto | M | 70 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Harald Deutsch | M | 62 |
Behringwerke AG
Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | 8 years |
| Fritz Flanderka | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Clemens Oertel | M | 54 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Christopher Delbrück | M | 57 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Hans-Sebastian Graf von Wallwitz | M | 59 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| John Pohlner | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Gregor Schulz | M | 74 |
Behringwerke AG
Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | 6 years |
| Hans-Heinrich Henneicke von Zepelin | M | 61 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Roland Kaplan | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Titus Weinheimer | M | 58 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Eric-Paul Pâques | M | 70 |
Behringwerke AG
Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | 13 years |
| Peter Gruss | M | 75 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Luis Miguel Cardozo Goytizolo | M | 73 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Joachim Müller | M | 65 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| John-Edward Butler-Ransohoff | M | - |
Ruprecht-Karls-Universität Heidelberg
| 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 32 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bernd Eisele
- Personal Network
